Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?
作者信息
Jongs Niels, Heerspink Hiddo J L
机构信息
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
出版信息
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):6-8. doi: 10.2215/CJN.0000000630. Epub 2024 Dec 12.
Abstract
摘要
相似文献
1
Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?改善临床试验中的患者选择：我们是否应开始将试验前估算肾小球滤过率（eGFR）下降作为风险富集标准？
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):6-8. doi: 10.2215/CJN.0000000630. Epub 2024 Dec 12.
2
Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults.常规使用患者报告结局指标（PROMs）以改善成人常见精神障碍的治疗。
Cochrane Database Syst Rev. 2016 Jul 13;7(7):CD011119. doi: 10.1002/14651858.CD011119.pub2.
3
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的表皮生长因子受体（EGFR）抑制剂
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
4
Environmental enrichment for stroke and other non-progressive brain injury.环境丰富化治疗卒中和其他非进行性脑损伤。
Cochrane Database Syst Rev. 2021 Nov 23;11(11):CD011879. doi: 10.1002/14651858.CD011879.pub2.
5
Laser therapy for retinopathy in sickle cell disease.激光疗法治疗镰状细胞病视网膜病变。
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.
6
Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.封闭系统药物转移装置加危险药物安全操作与仅进行安全操作相比，对减少医护人员接触输注性危险药物的影响
Cochrane Database Syst Rev. 2018 Mar 27;3(3):CD012860. doi: 10.1002/14651858.CD012860.pub2.
7
Cognitive behavioural therapy (CBT), third-wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents.基于认知行为疗法（CBT）、第三代CBT和人际治疗（IPT）的干预措施，用于预防儿童和青少年的抑郁症。
Cochrane Database Syst Rev. 2016 Aug 9;2016(8):CD003380. doi: 10.1002/14651858.CD003380.pub4.
8
Audio-visual presentation of information for informed consent for participation in clinical trials.用于参与临床试验知情同意的信息视听展示。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003717. doi: 10.1002/14651858.CD003717.pub2.
9
Cuffed versus uncuffed endotracheal tubes for general anaesthesia in children aged eight years and under.八岁及以下儿童全身麻醉时使用带套囊与不带套囊气管内导管的比较。
Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD011954. doi: 10.1002/14651858.CD011954.pub2.
10
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review.髋、膝或髋膝骨关节炎患者的运动干预和患者信念：一项混合方法综述
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD010842. doi: 10.1002/14651858.CD010842.pub2.
本文引用的文献
1
Albuminuria and Rapid Kidney Function Decline as Selection Criteria for Kidney Clinical Trials in Type 1 Diabetes Mellitus.白蛋白尿和肾功能快速下降作为1型糖尿病肾脏临床试验的入选标准。
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):62-71. doi: 10.2215/CJN.0000000000000567. Epub 2024 Nov 18.
2
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.一项随机、开放标签、临床试验使用个体干预前 eGFR 斜率来研究卡格列净对白蛋白尿和 eGFR 下降的影响。
Kidney Int. 2024 Nov;106(5):972-984. doi: 10.1016/j.kint.2024.08.019. Epub 2024 Aug 30.
3
Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Analysis from the SONAR Trial.临床试验入组前估算肾小球滤过率（eGFR）下降的患者间差异较大及其对阿曲生坦疗效的影响：来自SONAR试验的分析
J Am Soc Nephrol. 2021 Nov;32(11):2731-2734. doi: 10.1681/ASN.2021040498. Epub 2021 Aug 20.
4
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
5
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
6
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.阿曲生坦与伴有慢性肾脏疾病的 2 型糖尿病患者的肾脏事件（SONAR）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14.
7
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
Zotero 插件